TICKERNERD
Menu
DGXDGXHealthcare · Diagnostics & Research

DGX Stock Forecast: Quest Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$235
−0.02% on the day

The 17 Wall Street analysts covering Quest Diagnostics, Inc. hold a median 12-month price target of $250 — +6.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 8 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$26.2B
Ticker Nerd rank
94 / 100
Median analyst target
$250
Analysts covering
17
Revenue$3.0B+10.2% y/y
Operating income$459.0M
Net income$334.0M
Free cash flow$459.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.3%
1M
−1.2%
YTD
+37.5%
1Y
+31.1%
From 52W high
−3.9%
From 52W low
+37.5%
$171
$245
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Quest Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Revisions
97
Issuance
80
Quality
79
Momentum
78
Growth
68
Value
64
Accruals
61
Size
8

Volatility (99): The share price has been relatively steady.

Accruals (61): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$160$180$200$220$240$260$280Oct 25Jan 26Apr 26Jul 26DGXHigh $265Median $250Low $204

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
9 Buy7 Hold1 Sell
Low $204Median $250High $265

The green dot is the last close — the median target sits +6.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
28 July 2026JP MorganMaintainsNeutral$220 → $250
25 July 2026UBSMaintainsNeutral—
24 July 2026BairdMaintainsNeutral$236 → $255
24 July 2026BarclaysMaintainsOverweight$230 → $250
24 July 2026MizuhoMaintainsOutperform$235 → $260
24 July 2026Truist SecuritiesMaintainsHold$225 → $250
24 July 2026UBSMaintainsNeutral$220 → $232
13 July 2026BairdMaintainsNeutral$232 → $236
13 July 2026BairdMaintainsNeutral—
22 Apr 2026BairdMaintainsNeutral—
22 Apr 2026BarclaysMaintainsOverweight—
22 Apr 2026Truist SecuritiesMaintainsHold—
22 Apr 2026UBSMaintainsNeutral—
8 Apr 2026Evercore ISI GroupMaintainsIn-Line—
12 Feb 2026MizuhoMaintainsOutperform—
11 Feb 2026BarclaysMaintainsOverweight—
11 Feb 2026Evercore ISI GroupMaintainsIn-Line—
11 Feb 2026JefferiesMaintainsBuy—
11 Feb 2026Truist SecuritiesMaintainsHold—
11 Feb 2026UBSMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DGX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DGX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Quest Diagnostics, Inc. returned +31.1% against +18.5% for the S&P 500, dividends included.

DGX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Oct 25Jan 26Apr 26Jul 26DGXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.9%
Analysts raising
15
Analysts cutting
0
Fundamentals

Quest Diagnostics, Inc. (DGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.0×

Cheaper than 31% of US stocks

Price / sales
2.2×

Cheaper than 50% of US stocks

Price / book
3.4×

Cheaper than 30% of US stocks

EV / EBITDA
14.3×

Cheaper than 25% of US stocks

Growth & margins
Revenue growth (YoY)
10.2%

Higher than 52% of US stocks

Earnings growth (YoY)
13.5%

Higher than 52% of US stocks

Gross margin
33.7%

Higher than 40% of US stocks

Operating margin
15.2%

Higher than 73% of US stocks

Net margin
9.2%

Higher than 68% of US stocks

Returns & dividend
Return on equity
14.6%

Higher than 73% of US stocks

Return on assets
6.4%

Higher than 83% of US stocks

Dividend yield
1.5%

Higher than 34% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Quest Diagnostics, Inc. (DGX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Quest Diagnostics, Inc. has a market value of $26.2B and an enterprise value of $32.3B.

  • Revenue in the twelve months to 30 June 2026: $11.6B. The latest quarter grew 10.2% year on year.

  • Net income over the same four quarters: $1.1B, a 9.6% net margin.

  • Diluted earnings per share, trailing twelve months: $9.42.

  • Free cash flow in the twelve months to 30 June 2026: $1.3B, after $554.0M of capital spending.

  • Quest Diagnostics, Inc. spent $363.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 110.0M.

  • Trailing P/E: 25.0×; forward P/E: 19.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.45%, paying out 26% of earnings.

  • Quest Diagnostics, Inc. employs 46,000 people — $251K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

DGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
DGXQuest Diagnostics, Inc.$26.2B
94
LHLabcorp Holdings, Inc.$26.9B
86
MTDMettler-Toledo International, Inc.$27.1B
91
ILMNIllumina, Inc.$31.9B
95
GHGuardant Health, Inc.$20.8B
48
WATWaters Corp.$39.5B
52
MEDPMedpace Holdings, Inc.$16.9B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Quest Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DGX news & analysis

Apple Health app Users to be Able to Order Labs from Quest Diagnostics

PRNewsWire · 9 Sept 2026positive

Quest Diagnostics announced that Apple Health app users in the United States will later this year be able to purchase tailored Quest laboratory test panels covering over 50 biomarkers directly through the app on iPhone and iPad, with results delivered in the app.

Why it matters — This expands Quest's direct-to-consumer distribution channel through Apple's large-scale Health app user base, potentially broadening access to its lab testing services.

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

Zacks Investment Research · 8 Sept 2026neutral

Zacks Investment Research highlighted Oportun Financial, Uranium Royalty, and Amgen, along with standout gains from its key stock portfolios, in a piece about its approach to beating the markets. The item does not mention Quest Diagnostics.

Why it matters — DGX watchers may note that this commentary centers on other companies and general market strategy, carrying no direct implications for Quest Diagnostics.

Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million

The Motley Fool · 8 Sept 2026neutral

Quest Diagnostics' CEO sold 10,000 shares of DGX for an estimated value of approximately $2.4 million, based on the execution price on September 1, 2026. The shares traded represent 8% of the equity stake held directly by the executive prior to this filing.

Why it matters — A DGX watcher would care because insider share sales can offer a view into executive sentiment regarding the company's stock.

Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research · 31 Aug 2026positive

Zacks Investment Research highlighted Quest Diagnostics (DGX) as a top-ranked value stock using its Style Scores system, which helps investors identify highly rated stocks based on investing style.

Why it matters — A positive ranking from Zacks' Style Scores could draw attention from value-oriented investors and influence how the stock is perceived in the market.

Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference

PRNewsWire · 25 Aug 2026neutral

Quest Diagnostics announced that Chairman, CEO and President Jim Davis will speak about the company's strategy, performance, and market trends at the Baird 2026 Global Healthcare Conference in New York City on September 15, 2026.

Why it matters — The presentation offers DGX watchers an opportunity to hear directly from leadership on the company's strategy and current market developments.

FAQ

Frequently asked questions about DGX stock

What is the DGX stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Quest Diagnostics, Inc. have a median 12-month price target of $250, with estimates ranging from $204 to $265. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DGX stock a buy right now?

Of the 17 analysts covering Quest Diagnostics, Inc., 9 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Quest Diagnostics, Inc. 94 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DGX?

As at 8 Sept 2026, Quest Diagnostics, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will DGX stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +6.2% from the last close, and Ticker Nerd's factor model ranks Quest Diagnostics, Inc. 94 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DGX stock forecast for 2030?

No analyst covering Quest Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $204 to $265 over the next 12 months.

How has DGX stock performed over the past year?

Quest Diagnostics, Inc. returned +31.1% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Quest Diagnostics, Inc. do?

Quest Diagnostics Incorporated is a healthcare diagnostics company that provides diagnostic testing and related information services. Quest Diagnostics supports physicians, hospitals, patients, health plans, employers, and government agencies with routine clinical testing, advanced specialty testing, anatomic pathology, and consumer-ordered testing services.

What is the latest news on DGX?

The most recent item we track (PRNewsWire, 9 Sept 2026): "Apple Health app Users to be Able to Order Labs from Quest Diagnostics". Quest Diagnostics announced that Apple Health app users in the United States will later this year be able to purchase tailored Quest laboratory test panels covering over 50 biomarkers directly through the app on iPhone and iPad, with results delivered in the app.

Company

About Quest Diagnostics, Inc.

Quest Diagnostics Incorporated is a healthcare diagnostics company that provides diagnostic testing and related information services. Quest Diagnostics supports physicians, hospitals, patients, health plans, employers, and government agencies with routine clinical testing, advanced specialty testing, anatomic pathology, and consumer-ordered testing services. Its offerings include laboratory testing for areas such as cancer, heart disease, diabetes, infectious diseases, and genetic conditions, along with services for drug and alcohol screening, risk assessment, and healthcare information technology. The company operates a broad network of laboratories and patient service centers across the United States, helping connect sample collection, analysis, and reporting within the medical care process. Quest Diagnostics Incorporated plays a central role in the healthcare market by providing data and laboratory insights that support diagnosis, treatment decisions, and ongoing health management.

CEO Mr. James E. Davis · 46,000 employees · United States · https://www.questdiagnostics.com